Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Capital Employed (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Return on Capital Employed for 6 consecutive years, with 0.64% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed rose 6.0% year-over-year to 0.64%, compared with a TTM value of 0.64% through Sep 2025, up 6.0%, and an annual FY2024 reading of 0.58%, down 15.0% over the prior year.
  • Return on Capital Employed was 0.64% for Q3 2025 at Ovid Therapeutics, down from 0.59% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.82% in Q1 2021 and bottomed at 0.73% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 0.24%, with a median of 0.46% recorded in 2024.
  • The sharpest move saw Return on Capital Employed soared 199bps in 2021, then tumbled -103bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.67% in 2021, then tumbled by -154bps to 0.36% in 2022, then plummeted by -33bps to 0.48% in 2023, then tumbled by -48bps to 0.71% in 2024, then grew by 10bps to 0.64% in 2025.
  • Business Quant data shows Return on Capital Employed for OVID at 0.64% in Q3 2025, 0.59% in Q2 2025, and 0.73% in Q1 2025.